- Diagnos (ADK) is entering the fast-growing retinal diagnostics market with its new 3D image analysis technology
- The company’s multimodal data analysis tools take advantage of the most recent advancements in ophthalmic science
- It’s non-invasive and integrates the analysis of 3D cross-sectional images of the retina
- Diagnos provides software-based interpretation services to assist early detection of critical health problems
- Diagnos Inc. (ADK) is down 1.89 per cent, trading at C$0.26 per share at 12:26 pm ET
Diagnos (ADK) is entering the fast-growing retinal diagnostics market with its new 3D image analysis technology.
The company is pushing the boundaries of the practice with deep learning-powered technology. It is capable of diagnosing retinal conditions such as Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema, Retinal Cancer, and other retinal and macular diseases.
Moreover, neurological and systemic diseases affecting other parts of the body can also be identified. It includes Alzheimer’s disease, cardiovascular diseases, multiple sclerosis, Parkinson’s disease, etc.
The company’s multimodal data analysis tools take advantage of the most recent advancements in ophthalmic science. It combines data fetched from retinal images and optical coherence tomography (OCT) scans. The technology is more precise than MRI and ultrasound scanning. It’s non-invasive and integrates the analysis of 3D cross-sectional images of the retina.
Diagnos provides software-based interpretation services to assist early detection of critical health problems. It uses its FLAIRE platform based on Artificial Intelligence (AI). The company provides image analysis services through CARA (Computer Assisted Retinal Analysis).
Diagnos Inc. (ADK) is down 1.89 per cent, trading at C$0.26 per share at 12:26 pm ET.
